Stephen H Gray1, Jared A White2, Peng Li3, Meredith L Kilgore3, David T Redden3, Ahmed K Abdel Aal4, Heather N Simpson5, Brendan McGuire5, Devin E Eckhoff2, Derek A Dubay6. 1. Department of Surgery, Division of Abdominal Transplantation, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama. Electronic address: sgray@uabmc.edu. 2. Department of Surgery, Division of Abdominal Transplantation, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama. 3. School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama. 4. Department of Radiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama. 5. Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama. 6. Department of Surgery, Division of Transplant Surgery, Medical University of South Carolina, Charleston, South Carolina.
Abstract
PURPOSE: To measure transarterial chemoembolization utilization and survival benefit among patients with hepatocellular carcinoma (HCC) in the Surveillance, Epidemiology, and End Results (SEER) patient population. MATERIALS AND METHODS: A retrospective study identified 37,832 patients with HCC diagnosed between 1991 and 2011. Survival was estimated by Kaplan-Meier method and compared by log-rank test. Propensity-score matching was used to address an imbalance of covariates. RESULTS: More than 75% of patients with HCC did not receive any HCC-directed treatment. Transarterial chemoembolization was the most common initial therapy (15.9%). Factors associated with the use of chemoembolization included younger age, more HCC risk factors, more comorbidities, higher socioeconomic status, intrahepatic tumor, unifocal tumor, vascular invasion, and smaller tumor size (all P < .001). Median survival was improved in patients treated with chemoembolization compared with those not treated with chemoembolization (20.1 vs 4.3 mo; P < .0001). Similar findings were demonstrated in propensity-scoring analysis (14.5 vs 4.2 mo; P < .0001) and immortal time bias sensitivity analysis (9.5 vs 3.6 mo; P < .0001). There was a significantly improved survival hazard ratio (HR) in patients treated with chemoembolization (HR, 0.42; 95% confidence interval, 0.39-0.45). CONCLUSIONS: Patients with HCC treated with transarterial chemoembolization experienced a significant survival advantage compared with those not treated with transarterial chemoembolization. More than 75% of SEER/Medicare patients diagnosed with HCC received no identifiable oncologic treatment. There is a significant public health need to increase awareness of efficacious HCC treatments such as transarterial chemoembolization.
PURPOSE: To measure transarterial chemoembolization utilization and survival benefit among patients with hepatocellular carcinoma (HCC) in the Surveillance, Epidemiology, and End Results (SEER) patient population. MATERIALS AND METHODS: A retrospective study identified 37,832 patients with HCC diagnosed between 1991 and 2011. Survival was estimated by Kaplan-Meier method and compared by log-rank test. Propensity-score matching was used to address an imbalance of covariates. RESULTS: More than 75% of patients with HCC did not receive any HCC-directed treatment. Transarterial chemoembolization was the most common initial therapy (15.9%). Factors associated with the use of chemoembolization included younger age, more HCC risk factors, more comorbidities, higher socioeconomic status, intrahepatic tumor, unifocal tumor, vascular invasion, and smaller tumor size (all P < .001). Median survival was improved in patients treated with chemoembolization compared with those not treated with chemoembolization (20.1 vs 4.3 mo; P < .0001). Similar findings were demonstrated in propensity-scoring analysis (14.5 vs 4.2 mo; P < .0001) and immortal time bias sensitivity analysis (9.5 vs 3.6 mo; P < .0001). There was a significantly improved survival hazard ratio (HR) in patients treated with chemoembolization (HR, 0.42; 95% confidence interval, 0.39-0.45). CONCLUSIONS:Patients with HCC treated with transarterial chemoembolization experienced a significant survival advantage compared with those not treated with transarterial chemoembolization. More than 75% of SEER/Medicare patients diagnosed with HCC received no identifiable oncologic treatment. There is a significant public health need to increase awareness of efficacious HCC treatments such as transarterial chemoembolization.
Authors: Shimul A Shah; Jillian K Smith; Youfu Li; Sing Chau Ng; James E Carroll; Jennifer F Tseng Journal: Cancer Date: 2010-10-13 Impact factor: 6.860
Authors: Viktor V Chirikov; C Daniel Mullins; Nader Hanna; Ian M Breunig; Brian Seal; Fadia T Shaya Journal: Am J Clin Oncol Date: 2015-12 Impact factor: 2.339
Authors: Nathan Haywood; Kyle Gennaro; John Obert; Paul F Sauer; David T Redden; Jessica Zarzour; J Kevin Smith; David Bolus; Souheil Saddekni; Ahmed Kamel Abdel Aal; Stephen Gray; Jared White; Devin E Eckhoff; Derek A DuBay Journal: J Oncol Date: 2016-02-02 Impact factor: 4.375
Authors: Hakm Y Murad; Emma P Bortz; Heng Yu; Daishen Luo; Gray M Halliburton; Andrew B Sholl; Damir B Khismatullin Journal: Sci Rep Date: 2019-12-20 Impact factor: 4.379